This is a past event. Registration is closed. View other OBN events.

BioTrinity Programme Update:


"The OBN team are disappointed to announce that Minister George Freeman who was scheduled to present an address for the BioTrinity delegation on Tuesday 25 April, is unavailable to attend the conference in person due to unavoidable parliamentary business, requiring his presence in Westminster on Tuesday 25th and Wednesday 26th April. The Minister would have loved to have supported and found the time to provide a recorded address, but this has not been possible due to a packed diary in the run up to the coronation."

R&D Spotlight: Oncology
David BlakeyAlfie BrennanStuart FarrowMoritz HaneklausSalim KhakooPeter Llewellyn-DaviesFrances MurphyPhilip Beer

Kindly sponsored by Precision for Medicine

  • David Blakey (CSO at FasT Biopharma)

    David Blakey

    CSO at FasT Biopharma
  • Alfie Brennan (Principal Scientist at Evariste)

    Alfie Brennan

    Principal Scientist at Evariste
  • Stuart Farrow (Vice President of Biosciences at Cancer Research Horizons)

    Stuart Farrow

    Vice President of Biosciences at Cancer Research Horizons
  • Moritz Haneklaus (Senior Scientist at Macomics Limited)

    Moritz Haneklaus

    Senior Scientist at Macomics Limited
  • Salim Khakoo (Founder and CSO of Kargenera)

    Salim Khakoo

    Founder and CSO of Kargenera
  • Peter Llewellyn-Davies (CEO of invIOs GmbH)

    Peter Llewellyn-Davies

    CEO of invIOs GmbH
  • Frances Murphy (Regional Vice President, Clinical Business Solutions EU & APAC at Precision for Medicine)

    Frances Murphy

    Regional Vice President, Clinical Business Solutions EU & APAC at Precision for Medicine
  • Philip Beer (CSO at Step Pharma)

    Philip Beer

    CSO at Step Pharma
R&D Spotlight: Vaccines, Infectious Diseases & Microbiome
David BrowningRichard BungayNik SharmaJeremy SkillingtonKirsty SmittenDouglas ThomsonJonathan Pearce
  • David Browning (CEO of Fixed Phage)

    David Browning

    CEO of Fixed Phage
  • Richard Bungay (CEO of Imophoron Ltd)

    Richard Bungay

    CEO of Imophoron Ltd
  • Nik Sharma (Co-Founder CEO of BioCorteX)

    Nik Sharma

    Co-Founder CEO of BioCorteX
  • Jeremy Skillington (CEO of Poolbeg Pharma PLC)

    Jeremy Skillington

    CEO of Poolbeg Pharma PLC
  • Kirsty Smitten (CEO of MetalloBio)

    Kirsty Smitten

    CEO of MetalloBio
  • Douglas Thomson (CEO of Pneumagen Ltd)

    Douglas Thomson

    CEO of Pneumagen Ltd
  • Jonathan Pearce (CEO of Antibiotic Research UK)

    Jonathan Pearce

    CEO of Antibiotic Research UK
Lunch & Networking
Technical Update: Quantum Computing & Life Sciences
David GrimmSonali MohapatraJonathan Rohll

This session will feature a 15 minute presentation from Sonali Mohapatra, Quantum Innovation Sector Lead at the National Quantum Computing Centre (NQCC) on the potential impact that Quantum Computing will have on drug discovery. Followed by an investment update from David Grimm, Investment Director at Albion VC. David manages the UCL Technology Fund’s Computer and Physical Sciences investment team. Investing in a wide range of exciting deeptech opportunities, including Quantum Computing, Machine Learning and Data Analytics, Cleantech, Medtech, Edtech and Hardware.

There will be the opportunity for audience Q&A after the presentations.

  • David Grimm (Investment Director of UCL Technology Fund)

    David Grimm

    Investment Director of UCL Technology Fund
  • Sonali Mohapatra (Quantum Innovation Sector Lead at National Quantum Computing Centre)

    Sonali Mohapatra

    Quantum Innovation Sector Lead at National Quantum Computing Centre
  • Jonathan Rohll (Head of Science & Entrepreneur Advocate at OBN (UK) Ltd)

    Jonathan Rohll

    Head of Science & Entrepreneur Advocate at OBN (UK) Ltd
R&D Spotlight: Platforms
Robert GrundyAneesh Karatt VellattAnna Perdrix RosellMichael RobertsJonathan RohllArne Scheu
  • Robert Grundy (Vice President, Business Development at Intelligent OMICS)

    Robert Grundy

    Vice President, Business Development at Intelligent OMICS
  • Aneesh Karatt Vellatt (CSO and Co-founder of Maxion Therapeutics)

    Aneesh Karatt Vellatt

    CSO and Co-founder of Maxion Therapeutics
  • Anna Perdrix Rosell (co-CEO and co-founder of Sixfold Bioscience)

    Anna Perdrix Rosell

    co-CEO and co-founder of Sixfold Bioscience
  • Michael Roberts (CEO of Chromatin Bioscience)

    Michael Roberts

    CEO of Chromatin Bioscience
  • Jonathan Rohll (Head of Science & Entrepreneur Advocate at OBN (UK) Ltd)

    Jonathan Rohll

    Head of Science & Entrepreneur Advocate at OBN (UK) Ltd
  • Arne Scheu (Co-Founder & CEO of LiliumX)

    Arne Scheu

    Co-Founder & CEO of LiliumX
R&D Spotlight: Medtech
Alex BatchelorAlex CharitouGeorge FrodshamVictor HarabariAntoine PouppezMikesh Udani
  • Alex Batchelor (CEO of Pictura Bio Ltd)

    Alex Batchelor

    CEO of Pictura Bio Ltd
  • Alex Charitou (Partner | Life Sciences at EY)

    Alex Charitou

    Partner | Life Sciences at EY
  • George Frodsham (CEO of MediSieve Limited)

    George Frodsham

    CEO of MediSieve Limited
  • Victor Harabari (Founder and CEO of Cardiocrown)

    Victor Harabari

    Founder and CEO of Cardiocrown
  • Antoine Pouppez (CEO of NeuroClues)

    Antoine Pouppez

    CEO of NeuroClues
  • Mikesh Udani (CEO of Albus Health)

    Mikesh Udani

    CEO of Albus Health
R&D Spotlight: Rare Diseases
Rebecca AbramDaniel ChainLisa ConteAdrien LemoineJonathan ReesDan Williams

Kindly sponsored by FUJIFILM Diosynth Biotechnologies

  • Rebecca Abram (Director, Strategic Technical Marketing of Fujifilm Diosynth Biotechnologies)

    Rebecca Abram

    Director, Strategic Technical Marketing of Fujifilm Diosynth Biotechnologies
  • Daniel Chain (President & CEO of TauC3 Biologics Limited)

    Daniel Chain

    President & CEO of TauC3 Biologics Limited
  • Lisa Conte (President/CEO Jaguar Health and Chairman, BOD, Napo Therapeutics of Jaguar Health Inc.)

    Lisa Conte

    President/CEO Jaguar Health and Chairman, BOD, Napo Therapeutics of Jaguar Health Inc.
  • Adrien Lemoine (Chief Executive Officer & Co-Founder of Bloomsbury Genetic Therapies)

    Adrien Lemoine

    Chief Executive Officer & Co-Founder of Bloomsbury Genetic Therapies
  • Jonathan Rees (CEO of MitoRx Therapeutics Limited)

    Jonathan Rees

    CEO of MitoRx Therapeutics Limited
  • Dan Williams (CEO of SynaptixBio)

    Dan Williams

    CEO of SynaptixBio
R&D Spotlight: Neuroscience
Jenny BarnettChristophe GaudinPeter HamleySimon LoiodiceJerome ParcqJames PeachMimoun Azzouz
  • Jenny Barnett (CEO of Monument Therapeutics Limited)

    Jenny Barnett

    CEO of Monument Therapeutics Limited
  • Christophe Gaudin (CEO of Op2lysis)

    Christophe Gaudin

    CEO of Op2lysis
  • Peter Hamley (Chief Scientific Officer at Samsara Therapeutics Ltd)

    Peter Hamley

    Chief Scientific Officer at Samsara Therapeutics Ltd
  • Simon Loiodice (Co-Founder and CEO of Karla Tx)

    Simon Loiodice

    Co-Founder and CEO of Karla Tx
  • Jerome Parcq (Co-Founder of Op2lysis)

    Jerome Parcq

    Co-Founder of Op2lysis
  • James Peach (CEO of Human Centric DD Ltd)

    James Peach

    CEO of Human Centric DD Ltd
  • Mimoun Azzouz (Chair of Translational Neuroscience at University of Sheffield)

    Mimoun Azzouz

    Chair of Translational Neuroscience at University of Sheffield
R&D Spotlight: Oncology
Francesca RapinoGraeme RogersAlan RothSzabolcs NagyClare WareingIgor Matushansky

Kindly sponsored by Ipsen

  • Francesca Rapino (COO at Theratrame)

    Francesca Rapino

    COO at Theratrame
  • Graeme Rogers (Chief Scientific Officer at Omideon)

    Graeme Rogers

    Chief Scientific Officer at Omideon
  • Alan Roth (CEO of Oxford Drug Design)

    Alan Roth

    CEO of Oxford Drug Design
  • Szabolcs Nagy (Founder, CEO of Turbine AI)

    Szabolcs Nagy

    Founder, CEO of Turbine AI
  • Clare Wareing (Founder & Chief Executive Officer of Cumulus Oncology)

    Clare Wareing

    Founder & Chief Executive Officer of Cumulus Oncology
  • IM

    Igor Matushansky

    Global Head, Oncology Therapeutic Area at Ipsen
Technical Update: Targeted Protein DegradationProgress, Direction and Prospects
Sheelagh Frame
Lunch & Networking
R&D Spotlight: Inflammatory Disease
Mark DowlingMark PeakmanSalman RahmanJason RuttKirsty SempleThomas Mcinally

Kindly sponsored by Sanofi

  • Mark Dowling (Head External Innovation Immunology at Sanofi)

    Mark Dowling

    Head External Innovation Immunology at Sanofi
  • Mark Peakman (Head of Autoimmunity Cluster, Immunology & Inflammation Research at Sanofi)

    Mark Peakman

    Head of Autoimmunity Cluster, Immunology & Inflammation Research at Sanofi
  • Salman Rahman (CEO of Vasgen Ltd)

    Salman Rahman

    CEO of Vasgen Ltd
  • Jason Rutt (Founder and CEO of Azadyne)

    Jason Rutt

    Founder and CEO of Azadyne
  • Kirsty Semple (CEO of SENISCA Ltd)

    Kirsty Semple

    CEO of SENISCA Ltd
  • Thomas Mcinally (Director of Alevin Therapeutics Ltd)

    Thomas Mcinally

    Director of Alevin Therapeutics Ltd
R&D Spotlight: Cell & Gene Therapy
James Barwick-SilkSapan GandhiCarin IngemarsdotterVlad SeitanGiles Dudley

Kindly sponsored by Syneos Health

  • James Barwick-Silk (Director, Scientific Strategy, Cell & Gene Therapy of Syneos Health)

    James Barwick-Silk

    Director, Scientific Strategy, Cell & Gene Therapy of Syneos Health
  • Sapan Gandhi (Founder of Drishti Discoveries)

    Sapan Gandhi

    Founder of Drishti Discoveries
  • Carin Ingemarsdotter (Co-Founder and COO of Spliceor Therapeutics)

    Carin Ingemarsdotter

    Co-Founder and COO of Spliceor Therapeutics
  • Vlad Seitan (CSO at Laverock Therapeutics)

    Vlad Seitan

    CSO at Laverock Therapeutics
  • Giles Dudley (CBO at Stimuliver)

    Giles Dudley

    CBO at Stimuliver

BioTrinity Panels, Interviews & Keynotes

 

We aim to deliver a well-rounded programme of presentations, discussions, and debate around a variety of subject matters prevalent in the life sciences industry today. We include a mix of scientific focused topics, which either address the latest innovation and research, or matters that are popular and much talked about in the current mainstream landscape, along with pertinent updates on the financing and investment landscapes, as well as regulatory and legislative updates from leading voices and decision makers.

 

We cover a lot of ground, and the range is broad, but we aim to support our delegates by delivering a programme that is digestible, useful, and thought-provoking.


Each R&D spotlight will include 5 x 10 minute company presentations from the most innovative companies working in; Oncology, Infectious Diseases, Microbiome, Rare Diseases, Medtech, Neuroscience, Inflammatory Disease and Cell and Gene Therapy. If you are a company seeking Series A investment or to partner assets, BioTrinity is for you! Contact events@obn.org.uk


Detailed below is an outline of all of the sessions, if you have any queries then please email events@obn.org.uk